COVID-19 Seroconversion Study Among GHdC Staff Members

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2817 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-20

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The management of the Grand Hôpital de Charleroi hospital authorized the performance of a serology for each member of the establishment's staff in order to better characterize the proportion of its employees who have already been in contact with the SARS CoV-2 virus for organizational and evaluation purposes symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 Among Healthcare Workers in Belgian Hospitals

NCT04373889

SARS-CoV-2 COVID-19

COMPLETED

Health Professional Exposure Assessment to Covid-19

NCT04429724

COVID-19

COMPLETED NA

poSt Covid-19 Infection centraL Sensitisation 2

NCT04701892

Covid19

UNKNOWN

Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms

NCT04356586

COVID-19 Serology

COMPLETED

Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers

NCT04370119

SARS-CoV-2

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At the start of the SARS-CoV-2 pandemic, several workers had symptoms compatible with COVID-19 at a time when PCR (smear) testing was only allowed for hospitalized people. In addition, the PCR test has a fairly low sensitivity. In this context, serology can make it possible to determine whether the symptoms are indeed linked to exposure to SARS-CoV-2.

As a hospital, and in order to prepare for a possible second epidemic wave, it is also useful to know the proportion of staff members who have already been in contact with the virus for organizational purposes and symptom assessment.

.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Serological tests

All staff at GHdC who want to know their level of antibodies against SARS CoV-2

Group Type EXPERIMENTAL

Serological tests for SARS Cov-2

Intervention Type DIAGNOSTIC_TEST

Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serological tests for SARS Cov-2

Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be a member of the staff of the Grand Hôpital de Charleroi who wishes to participate in order to know their immunity related to SARS CoV-2 after the first wave of pandemic.